Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease

Hyun Jung Lee, Jae Hyun Kim, Seung Won Kim, Hyun Ah Joo, Hye Won Lee, You Sun Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Young Ho Kim, JaeHee Cheon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Behçet’s disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. Methods: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. Results: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. Conclusions: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.

Original languageEnglish
Pages (from-to)1953-1962
Number of pages10
JournalDigestive diseases and sciences
Volume62
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Serum Amyloid A Protein
Intestinal Diseases
Proteomics
Serum
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Proteins
Mass Spectrometry
Biomarkers
HT29 Cells
Computational Biology
Fibrin
Interleukin-1
Lipopolysaccharides
Electrophoresis
Blood Proteins
Lasers
Tumor Necrosis Factor-alpha
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Lee, Hyun Jung ; Kim, Jae Hyun ; Kim, Seung Won ; Joo, Hyun Ah ; Lee, Hye Won ; Kim, You Sun ; Park, Soo Jung ; Hong, Sung Pil ; Kim, Tae Il ; Kim, Won Ho ; Kim, Young Ho ; Cheon, JaeHee. / Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease. In: Digestive diseases and sciences. 2017 ; Vol. 62, No. 8. pp. 1953-1962.
@article{6713bed4ceea47feaa212144fde4bd94,
title = "Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Beh{\cc}et’s Disease",
abstract = "Background/Aims: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Beh{\cc}et’s disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. Methods: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. Results: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. Conclusions: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.",
author = "Lee, {Hyun Jung} and Kim, {Jae Hyun} and Kim, {Seung Won} and Joo, {Hyun Ah} and Lee, {Hye Won} and Kim, {You Sun} and Park, {Soo Jung} and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho} and Kim, {Young Ho} and JaeHee Cheon",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s10620-017-4606-y",
language = "English",
volume = "62",
pages = "1953--1962",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "8",

}

Lee, HJ, Kim, JH, Kim, SW, Joo, HA, Lee, HW, Kim, YS, Park, SJ, Hong, SP, Kim, TI, Kim, WH, Kim, YH & Cheon, J 2017, 'Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease', Digestive diseases and sciences, vol. 62, no. 8, pp. 1953-1962. https://doi.org/10.1007/s10620-017-4606-y

Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease. / Lee, Hyun Jung; Kim, Jae Hyun; Kim, Seung Won; Joo, Hyun Ah; Lee, Hye Won; Kim, You Sun; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Kim, Young Ho; Cheon, JaeHee.

In: Digestive diseases and sciences, Vol. 62, No. 8, 01.08.2017, p. 1953-1962.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease

AU - Lee, Hyun Jung

AU - Kim, Jae Hyun

AU - Kim, Seung Won

AU - Joo, Hyun Ah

AU - Lee, Hye Won

AU - Kim, You Sun

AU - Park, Soo Jung

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Kim, Young Ho

AU - Cheon, JaeHee

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background/Aims: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Behçet’s disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. Methods: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. Results: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. Conclusions: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.

AB - Background/Aims: Data regarding biomarkers to understand disease pathogenesis and to assess disease activity of intestinal Behçet’s disease (BD) are limited. Therefore, we aimed to investigate the differentially expressed proteins in sera from patients with intestinal BD and to search for biomarkers using mass spectrometry-based proteomic analysis. Methods: Serum samples were pooled for the screening study, and two-dimensional electrophoresis (2-DE) was performed to characterize the proteins present in intestinal BD patients. Candidate protein spots were identified using matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF MS) and bioinformatic analysis. To validate the proteomic results, serum samples from an independent cohort were assessed by enzyme-linked immunosorbent assay. Results: Pooled serum samples were used for 2-DE, and approximately 400 protein spots were detected in the sera of intestinal BD patients. Of the 22 differentially expressed proteins, 3 were successfully identified using MALDI-TOF/TOF MS. The three up-regulated proteins identified in the intestinal BD group included fibrin, apolipoprotein A-IV, and serum amyloid A (SAA). Serum SAA in intestinal BD patients (2.76 ± 2.50 ng/ml) was significantly higher than that in controls (1.68 ± 0.90 ng/ml, p = 0.007), which is consistent with the proteomic results. In addition, the level of IL-1β in patients with intestinal BD (8.96 ± 1.23 pg/ml) was higher than that in controls (5.40 ± 0.15 pg/ml, p = 0.009). SAA released by HT-29 cells was markedly increased by tumor necrosis factor-α (TNF-α) and lipopolysaccharides stimulation. Conclusions: Our proteomic analysis revealed that SAA was up-regulated in intestinal BD patients.

UR - http://www.scopus.com/inward/record.url?scp=85019564916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019564916&partnerID=8YFLogxK

U2 - 10.1007/s10620-017-4606-y

DO - 10.1007/s10620-017-4606-y

M3 - Article

C2 - 28523576

AN - SCOPUS:85019564916

VL - 62

SP - 1953

EP - 1962

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 8

ER -